2,495,203 Shares in MabVax Therapeutics Holdings, Inc. (MBVX) Acquired by Cambridge Investment Research Advisors Inc.

Cambridge Investment Research Advisors Inc. acquired a new position in shares of MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 2,495,203 shares of the company’s stock, valued at approximately $1,622,000. Cambridge Investment Research Advisors Inc. owned approximately 12.33% of MabVax Therapeutics Holdings as of its most recent SEC filing.

TRADEMARK VIOLATION NOTICE: “2,495,203 Shares in MabVax Therapeutics Holdings, Inc. (MBVX) Acquired by Cambridge Investment Research Advisors Inc.” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another site, it was illegally stolen and reposted in violation of international copyright legislation. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2017/11/21/2495203-shares-in-mabvax-therapeutics-holdings-inc-mbvx-acquired-by-cambridge-investment-research-advisors-inc.html.

Shares of MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) traded down $0.03 during trading on Tuesday, hitting $0.65. The stock had a trading volume of 158,100 shares, compared to its average volume of 239,713. The company has a quick ratio of 0.54, a current ratio of 0.54 and a debt-to-equity ratio of 0.80. MabVax Therapeutics Holdings, Inc. has a 1-year low of $0.43 and a 1-year high of $4.25.

MabVax Therapeutics Holdings (NASDAQ:MBVX) last issued its earnings results on Tuesday, November 7th. The company reported ($0.54) EPS for the quarter. analysts predict that MabVax Therapeutics Holdings, Inc. will post -3.01 earnings per share for the current fiscal year.

About MabVax Therapeutics Holdings

MabVax Therapeutics Holdings, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers.

Receive News & Ratings for MabVax Therapeutics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MabVax Therapeutics Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply